No Data
No Data
WPRT, FIVN and FATE Are Among After Hour Movers
Truist Financial Reaffirms Their Hold Rating on AnaptysBio (ANAB)
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's Is How to Trade
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60).The company reported sales of $9.01 million, surpassing the consensus
Express News | AnaptysBio Shares Are Trading Higher After Wedbush Upgraded the Stock From Neutral to Outperform
No Data